Kairos Pharma Enters Binding Terms to Acquire CL-273
Kairos Pharma announces that it has entered into binding terms to acquire CL-273 from Celyn Therapeutics, a company backed by OrbiMed and Torrey Pines Investment. John Yu, M.D., Kairos Pharma CEO, commented: "The signing of binding terms to acquire CL-273 represents a pivotal step in building Kairos Pharma's next generation of targeted therapies for EGFR-mutant lung cancer. This transaction is expected to be value-accretive. CL-273's AI-designed, wild-type-sparing pan-EGFR profile positions it as a potentially best-in-class asset in a large, fast-growing $16.2 billion lung cancer market with significant unmet needs due to the development of resistance. Given its prestigious backing, we believe partnering with Celyn Therapeutics offers additional high-quality science to our existing pipeline. We believe in the rigor of the data package supporting CL-273. We further believe that together with an OrbiMed-backed innovator, Kairos Pharma is strongly positioned to deliver a highly differentiated, potentially best-in-class, EGFR inhibitor to patients worldwide."
Trade with 70% Backtested Accuracy
Analyst Views on KAPA
About KAPA
About the author
Kairos Pharma Acquires CL-273 to Expand Oncology Pipeline
- Significant Market Opportunity: Kairos Pharma's acquisition of CL-273 targets a projected $16.2 billion EGFR-mutant lung cancer market by 2026, indicating a strategic positioning in the rapidly growing oncology therapeutics sector.
- Innovative Technical Advantage: CL-273 is an AI-designed pan-EGFR inhibitor specifically engineered for EGFR-mutant non-small cell lung cancer, expected to become a best-in-class asset addressing the urgent need for therapies against resistant mutations.
- Strengthened Partnerships: The collaboration with Celyn Therapeutics, backed by OrbiMed, enhances Kairos Pharma's research capabilities and is anticipated to accelerate the clinical development timeline for new therapies.
- Leadership Confidence: CEO John Yu stated that this acquisition is expected to be value-accretive, reflecting Kairos Pharma's long-term commitment and competitive edge in the oncology market.
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
Kairos Pharma to Acquire Oncology Assets from Celyn Therapeutics
- Acquisition Agreement: Kairos Pharma Ltd. announced the signing of a term sheet to acquire two clinical oncology assets from Celyn Therapeutics, specifically CL-273 and CL-741, aimed at addressing non-small cell lung cancer (NSCLC), one of the most prevalent and challenging cancers globally.
- Significant Market Potential: The market for kinase inhibitors in cancer treatment is projected to reach $60.7 billion by 2025, with EGFR inhibitors accounting for 32.5%, while CL-273 targets the EGFR-mutated lung cancer segment, expected to be valued at $16.2 billion by 2026, indicating substantial market opportunities.
- Innovative Treatment Strategy: Kairos aims to combine a pan-EGFR inhibitor with a c-MET inhibitor to overcome drug resistance in NSCLC, deepening tumor responses and extending progression-free survival, a strategy that aligns with AstraZeneca's SAVANNAH trial, underscoring its scientific rationale.
- Utilization of Clinical Infrastructure: CEO John Yu stated that if the acquisition is completed, it would significantly expand the company's pipeline and leverage the clinical infrastructure at Cedars-Sinai Medical Center to accelerate Phase 1 and Phase 2 studies, further solidifying its competitive position in the multi-billion-dollar lung cancer market.
Kairos Pharma Wins 2025 Clinical Trials Arena R&D Award for Advanced Prostate Cancer
- Award Recognition: Kairos Pharma has been awarded the 2025 Clinical Trials Arena R&D Award for its innovative therapy ENV-105 in metastatic castration-resistant prostate cancer, highlighting its leadership in cancer treatment.
- Clinical Trial Results: In the Phase 2 trial of ENV-105 combined with apalutamide, 86% of patients showed clinical benefit, with all responders remaining progression-free for at least four months and some beyond one year, indicating the therapy's potential in patients with limited options.
- Targeted Therapy Strategy: ENV-105, as the first CD105-targeting monoclonal antibody, aims to overcome resistance following standard hormone treatments, emphasizing Kairos Pharma's innovative approach and scientific rigor in cancer therapy.
- Future Development Potential: The CEO of Kairos Pharma noted that the emerging clinical data supports the potential to extend disease control, offering new hope for patients facing treatment resistance and further advancing the company's strategic development in the biopharmaceutical sector.
D. Boral Capital Reiterates Buy Rating on Kairos Pharma with $9 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing collaboration and information sharing.
Market Winning Tools: Traders utilize Benzinga Pro's tools to gain a competitive edge and improve their trading success.
D. Boral Capital Upholds Buy Rating for Kairos Pharma (KAPA)
Analyst Recommendation: D. Boral Capital has maintained a Buy recommendation for Kairos Pharma (NYSEAM:KAPA), with a projected one-year price target of $8.50/share, indicating a potential upside of 632.76% from its current price of $1.16/share.
Fund Sentiment and Ownership: There has been a 44.44% increase in the number of funds reporting positions in Kairos Pharma, although total shares owned by institutions decreased by 84.77% over the last three months, with notable holdings from firms like XTX Topco and Aptus Capital Advisors.
Kairos Pharma Acquires CL-273 to Expand Oncology Pipeline
- Significant Market Opportunity: Kairos Pharma's acquisition of CL-273 targets a projected $16.2 billion EGFR-mutant lung cancer market by 2026, indicating a strategic positioning in the rapidly growing oncology therapeutics sector.
- Innovative Technical Advantage: CL-273 is an AI-designed pan-EGFR inhibitor specifically engineered for EGFR-mutant non-small cell lung cancer, expected to become a best-in-class asset addressing the urgent need for therapies against resistant mutations.
- Strengthened Partnerships: The collaboration with Celyn Therapeutics, backed by OrbiMed, enhances Kairos Pharma's research capabilities and is anticipated to accelerate the clinical development timeline for new therapies.
- Leadership Confidence: CEO John Yu stated that this acquisition is expected to be value-accretive, reflecting Kairos Pharma's long-term commitment and competitive edge in the oncology market.
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
Kairos Pharma to Acquire Oncology Assets from Celyn Therapeutics
- Acquisition Agreement: Kairos Pharma Ltd. announced the signing of a term sheet to acquire two clinical oncology assets from Celyn Therapeutics, specifically CL-273 and CL-741, aimed at addressing non-small cell lung cancer (NSCLC), one of the most prevalent and challenging cancers globally.
- Significant Market Potential: The market for kinase inhibitors in cancer treatment is projected to reach $60.7 billion by 2025, with EGFR inhibitors accounting for 32.5%, while CL-273 targets the EGFR-mutated lung cancer segment, expected to be valued at $16.2 billion by 2026, indicating substantial market opportunities.
- Innovative Treatment Strategy: Kairos aims to combine a pan-EGFR inhibitor with a c-MET inhibitor to overcome drug resistance in NSCLC, deepening tumor responses and extending progression-free survival, a strategy that aligns with AstraZeneca's SAVANNAH trial, underscoring its scientific rationale.
- Utilization of Clinical Infrastructure: CEO John Yu stated that if the acquisition is completed, it would significantly expand the company's pipeline and leverage the clinical infrastructure at Cedars-Sinai Medical Center to accelerate Phase 1 and Phase 2 studies, further solidifying its competitive position in the multi-billion-dollar lung cancer market.
Kairos Pharma Wins 2025 Clinical Trials Arena R&D Award for Advanced Prostate Cancer
- Award Recognition: Kairos Pharma has been awarded the 2025 Clinical Trials Arena R&D Award for its innovative therapy ENV-105 in metastatic castration-resistant prostate cancer, highlighting its leadership in cancer treatment.
- Clinical Trial Results: In the Phase 2 trial of ENV-105 combined with apalutamide, 86% of patients showed clinical benefit, with all responders remaining progression-free for at least four months and some beyond one year, indicating the therapy's potential in patients with limited options.
- Targeted Therapy Strategy: ENV-105, as the first CD105-targeting monoclonal antibody, aims to overcome resistance following standard hormone treatments, emphasizing Kairos Pharma's innovative approach and scientific rigor in cancer therapy.
- Future Development Potential: The CEO of Kairos Pharma noted that the emerging clinical data supports the potential to extend disease control, offering new hope for patients facing treatment resistance and further advancing the company's strategic development in the biopharmaceutical sector.
D. Boral Capital Reiterates Buy Rating on Kairos Pharma with $9 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing collaboration and information sharing.
Market Winning Tools: Traders utilize Benzinga Pro's tools to gain a competitive edge and improve their trading success.
D. Boral Capital Upholds Buy Rating for Kairos Pharma (KAPA)
Analyst Recommendation: D. Boral Capital has maintained a Buy recommendation for Kairos Pharma (NYSEAM:KAPA), with a projected one-year price target of $8.50/share, indicating a potential upside of 632.76% from its current price of $1.16/share.
Fund Sentiment and Ownership: There has been a 44.44% increase in the number of funds reporting positions in Kairos Pharma, although total shares owned by institutions decreased by 84.77% over the last three months, with notable holdings from firms like XTX Topco and Aptus Capital Advisors.
